logo
Plus   Neg
Share
Email

Eli Lilly Says Phase III Study Of Cialis Meets Primary Endpoint - Quick Facts

Eli Lilly & Co (LLY) Tuesday announced that a Phase III study showed both Cialis and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia, or BPH.

The randomized, double-blind, placebo-controlled, parallel-group, 12-week trial, conducted in 44 urology centers in 10 countries, assessed the efficacy and safety of Cialis 5 mg for daily use in parallel with tamsulosin 0.4 mg in men aged 45 years and older with signs and symptoms of BPH.

The company stated that Cialis improved erectile dysfunction in those men who had both signs and symptoms of BPH and ED.

The study also showed that maximum urinary flow rate increased significantly versus placebo with both Cialis and tamsulosin.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health... The Coca-Cola Company (KO) reported that its first-quarter comparable earnings per share from continuing operations grew 8% year-over-year to $0.47. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.46 for the quarter. Analysts' estimates typically exclude special items. Net income from continuing operations increased 12% to $1.33 billion. Earnings per share from continuing operations rose 13% to $0.31.
Follow RTT